Condition
Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Recruiting3
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07486206Not ApplicableRecruiting
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
NCT07482917Not ApplicableRecruiting
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
NCT07486869Phase 2Not Yet Recruiting
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
NCT07323732Phase 2Recruiting
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Showing all 4 trials